GLP-1 initiation is associated with a 14.6% reduced risk of asthma exacerbation for overweight patients, 12.2% for obese patients and 13.3% for morbidly obese patients Feb. 15, 2026 -- Glucagon-like peptide-1 receptor agonists (GLP-1) is linked to a significant reduction in asthma exacerbations for overweight, obese and morbidly obese patients without diabetes, according to new research being presented at the 2026 AAAAI Annual Meeting. "Asthma exacerbations can be disruptive for patients, espe

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development of this innovative immunotherapy. The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes 15 cohorts evaluating both monotherapy and comb

Gilead is buying the global rights to an oral cancer drug from Genhouse Bio, a China-based biotech that filed for an IPO on the Hong Kong Stock Exchange last month. The California drugmaker is dishing out $80 million upfront for GH31, a MAT2A-targeted synthetic lethality drug for select solid tumors. MAT2A plays a role in metabolic regulation and can be overexpressed in cancer cells. Genhouse could get up to $1.45 billion in biobucks, the company announced Friday on WeChat. A Gilead spokespers

Feb. 13, 2026-- A newly published scientific paper titled " Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G. Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration. Int. J. Mol. Sci. 2025, 26, 10969. https://doi.org/10.3390/ijms262210969) has validated a groundbreaking mechanism that has been at the core of HYD LLC for Cancer Research and Drug

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation DMD after receiving feedback on its filing from the regulator. "FDA shared that based on its review to date, the data in the [New Drug Application] submission are unlikely to meet the Agency's threshold of substantial evidence of effe

Novel intravenous anti-inflammatory candidate advances to Phase I evaluation to assess safety, tolerability, and pharmacokinetics. February 11, 2026-- Isosceles Pharmaceuticals today announced that its patented investigational candidate, IPI201, has been accepted to proceed into a Phase I first-in-human clinical trial, marking a milestone in the company’s development pipeline. The study is expected to initiate first patient, first dose in April, beginning with dosing in healthy volunteers. IPI

Neurent Medical, a company that has created a minimally invasive solution to treat chronic rhinitis, has raised $74 million in an oversubscribed Series C round. The Galway, Ireland-based company said it will use the funding to drive commercial expansion, broaden clinical evidence, and advance its product and indication pipeline. Neurent has developed Neuromark. The product uses a proprietary Impedance Controlled Radiofrequency technology targets the overactive posterior nasal nerves (PNN) that

Study to be conducted by PharmaLegacy, a leading Contract Research Organization February 11, 2026 -- Vidac Pharma Holding Plc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting the HK2/VDAC metabolic checkpoint, today announced the initiation of an in vivo pre-clinical program in psoriasis, marking the first formal evaluation of its proprietary technology platform outside oncology. The study will be conducted by PharmaLegacy, a highly reputable Contract

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the US BCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 Feb. 11, 2026 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of photod

First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma A parallel trial focused on gastroesophageal cancers, FAPI-GO, dosed its first patient December 2025 Feb. 11, 2026 -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the second of its two Phase 3 clinical trials evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein